Filing Details

Accession Number:
0001410939-22-000105
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-11-03 20:00:01
Reporting Period:
2022-11-01
Accepted Time:
2022-11-03 20:00:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1410939 Iveric Bio Inc. ISEE Pharmaceutical Preparations (2834) 208185347
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1696429 Keith Westby C/O Iveric Bio, Inc.
8 Sylvan Way
Parsippany NJ 07054
Svp & Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-11-01 42,916 $1.45 142,044 No 4 M Direct
Common Stock Disposition 2022-11-01 72,916 $23.92 69,128 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2022-11-01 42,916 $0.00 42,916 $1.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
27,084 2028-12-11 No 4 M Direct
Footnotes
  1. The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021.
  2. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $23.49 to $24.22 per share on November 1, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
  3. This stock option award was granted on December 12, 2018 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.